Repligen Corporation Company Profile
NASDAQ: RGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Repligen at a glance
Repligen Corporation (NASDAQ: RGEN) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Waltham, MA. Repligen is led by Mr. Olivier Loeillot and employs about 2,000 people. The company's shares have traded publicly since 1986.
At a market capitalization of $10.40 billion, it is considered a large-cap company. Its SEC Central Index Key (CIK) is 0000730272, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Repligen do?
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Repligen Corporation
- Ticker
- NASDAQ: RGEN
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Olivier Loeillot
- Employees
- 2,000
- Headquarters
- Building 1, Waltham, MA, United States
- Phone
- 781 250 0111
- Website
- repligen.com
- IPO year
- 1986
- Market cap
- $10.40B
- SEC CIK
- 0000730272
Companies similar to Repligen
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IBRXImmunityBio Inc. | 9.91 | +1.64% | $10.50B | vs RGEN |
| TWSTTwist Bioscience Corporation | 152.05 | -2.31% | $10.08B | vs RGEN |
| KRYSKrystal Biotech Inc. | 327.30 | +0.84% | $9.69B | vs RGEN |
| PCVXVaxcyte Inc. | 65.02 | -2.90% | $9.67B | vs RGEN |
| TECHBio-Techne Corp | 72.45 | -0.11% | $11.36B | vs RGEN |
| QGENQiagen N.V. | 44.53 | -0.58% | $9.20B | vs RGEN |
| KYMRKymera Therapeutics Inc. | 109.30 | +0.88% | $8.99B | vs RGEN |
| HALOHalozyme Therapeutics Inc. | 109.84 | -0.86% | $12.47B | vs RGEN |